person · Reporting owner

Elkins David V

Disclosed activity across 3 companies

Tapewire entity: 14775
SEC CIK: 0001451604

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BRISTOL MYERS SQUIBB COBMY · Entity 1662	EVP, Chief Financial Officer	April 01, 2026	April 02, 2026
TAPESTRY, INC.TPR · Entity 2309	Director	November 13, 2025	November 14, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BRISTOL MYERS SQUIBB CO

Report date April 01, 2026 · Filed April 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.10 par valueSEC Table I · non-derivative	Direct	159,248	Ending reported balance After 2026-04-01 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-04-01 · Sale · Disposed 25,519 · Balance 163,729 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2025. F2: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $60.900 to $61.895, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Row 2 · 2026-04-01 · Sale · Disposed 4,481 · Balance 159,248 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2025. F3: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $61.910 to $62.201, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
Common Stock, $0.10 par valueSEC Table I · non-derivative	IndirectBMS Savings and Investment Program	294.42	Reported balance Holding disclosure · report date 2026-04-01 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 294.42 F4: Based on recent 401(k) plan statement.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2025.

F2: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $60.900 to $61.895, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

F3: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $61.910 to $62.201, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

F4: Based on recent 401(k) plan statement.

TAPESTRY, INC.

Report date November 13, 2025 · Filed November 14, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	7,347	Reported balance After 2025-11-13 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2025-11-13 · Grant · Acquired 1,985 · Balance 7,347 F1: All of these securities acquired were received in the form of unvested restricted stock units issued under the Issuer's Stock Incentive Plan. These securities will vest on November 13, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: All of these securities acquired were received in the form of unvested restricted stock units issued under the Issuer's Stock Incentive Plan. These securities will vest on November 13, 2026.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CELGENE CORP /DE/

Report date November 20, 2019 · Filed November 22, 2019

Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2019-11-20 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2019-11-20 · Grant · Acquired 6,652 · Balance 20,560 F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Row 2 · 2019-11-20 · Grant · Acquired 11,088 · Balance 31,648 F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Row 3 · 2019-11-20 · Grant · Acquired 25,484 · Balance 57,132 F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Row 4 · 2019-11-20 · Disposition to issuer · Disposed 57,132 · Balance 0 F2: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
Common StockSEC Table I · non-derivative	Indirect401(k)	Reported balance After 2019-11-20 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2019-11-20 · Disposition to issuer · Disposed 195 · Balance 0 F2: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.19 · Expires 2028-08-01	Direct	Reported balance After 2019-11-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-11-20 · Disposition to issuer · Disposed 103,913 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-11-20 · Disposition to issuer · Disposed 49,895 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-11-20 · Disposition to issuer · Disposed 39,642 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

F2: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.

F3: This option was fully exercisable.

F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.

F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 20, 2019 Filed Nov 27, 2019 22:56 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	47,400	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000231 · wf-form4_157489535031849.xml · derivative · entry 7 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,400 Underlying: Common Stock, $0.10 par value · 47,400 shares Expires 2022-03-01 F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F7 · derivative.exercise_price: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award. F10 · derivative.exercise_price: The restricted stock unit vests in full on March 1, 2022, which is the end of the original performance period associated with the original Performance Share Unit award. F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F8 · derivative.exercise_date: The restricted stock unit vests in full on August 1, 2021, which is the end of the original performance period associated with the original Performance Share Unit award. F10 · derivative.exercise_date: The restricted stock unit vests in full on March 1, 2022, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:56 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	73,735	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000231 · wf-form4_157489535031849.xml · derivative · entry 6 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,735 Underlying: Common Stock, $0.10 par value · 73,735 shares Expires 2022-03-01 F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F9 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on March 1, 2020. F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F9 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on March 1, 2020. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:56 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	32,995	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000231 · wf-form4_157489535031849.xml · derivative · entry 5 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,995 Underlying: Common Stock, $0.10 par value · 32,995 shares Expires 2021-08-01 F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F7 · derivative.exercise_price: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award. F8 · derivative.exercise_price: The restricted stock unit vests in full on August 1, 2021, which is the end of the original performance period associated with the original Performance Share Unit award. F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F7 · derivative.exercise_date: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award. F8 · derivative.exercise_date: The restricted stock unit vests in full on August 1, 2021, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:56 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	92,805	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000231 · wf-form4_157489535031849.xml · derivative · entry 4 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,805 Underlying: Common Stock, $0.10 par value · 92,805 shares Expires 2021-08-01 F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F6 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on August 1, 2019. F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F6 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on August 1, 2019. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:56 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	193,277	$0.00 Strike: $48.49	$0.00	Disclosure SEC source: 0000014272-19-000231 · wf-form4_157489535031849.xml · derivative · entry 3 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,277 Underlying: Common Stock, $0.10 par value · 193,277 shares Expires 2028-08-01 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:56 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantCommon Stock, $0.10 par value	195	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000231 · wf-form4_157489535031849.xml · nonDerivative · entry 2 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · 401K Disclosed balance after: 195 F3 · shares: Based on a plan statement as of the end of the most recent fiscal quarter. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:56 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantCommon Stock, $0.10 par value	13,908	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000231 · wf-form4_157489535031849.xml · nonDerivative · entry 1 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,908 F1 · shares: On November 20, 2019 ("Closing Date"), Bristol-Myers Squibb Company ("BMS") completed the previously announced acquisition of Celgene Corporation ("Celgene") contemplated pursuant to the terms and conditions of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 2, 2019, by and among BMS, Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), and Celgene. Under the Merger Agreement, Merger Sub merged with and into Celgene with Celgene surviving as a direct wholly owned subsidiary of BMS (the "Merger"). The transactions on this form were not reported in a timely manner due to an administrative delay in calculations surrounding the total Merger Consideration (defined below) received by the Reporting Person. F2 · shares: Pursuant to the Merger, each outstanding share of Celgene common stock, par value $0.01 per share, was converted into the right to receive (x) $50 in cash, without interest, (y) one share of BMS common stock, par value $0.10 per share and (z) one tradeable contingent value right ( "CVR") per share or, with respect to equity awards (in some cases), per share underlying each such equity award ("Merger Consideration"). Each CVR will represent the right to receive $9.00 in cash upon Federal Drug Administration ("FDA") approval of a specified set of milestones, as set forth in the Contingent Value Rights Agreement, dated as of November 20, 2019, between BMS and Equiniti Trust Company, as trustee. Read SEC document
November 20, 2019 Filed Jan 4, 2020 01:37 UTC Amendment	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	47,401	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000035 · wf-form4a_157810184271109.xml · derivative · entry 3 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,401 Underlying: Common Stock, $0.10 par value · 47,401 shares Expires 2021-12-31 F1 · derivative.exercise_price: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award. F4 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F7 · derivative.exercise_price: The restricted stock unit vests in full on December 31, 2021, which is the end of the original performance period associated with the original Performance Share Unit award. F1 · derivative.exercise_date: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award. F4 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F7 · derivative.exercise_date: The restricted stock unit vests in full on December 31, 2021, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document
November 20, 2019 Filed Jan 4, 2020 01:37 UTC Amendment	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	20,624	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000035 · wf-form4a_157810184271109.xml · derivative · entry 2 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,624 Underlying: Common Stock, $0.10 par value · 20,624 shares Expires 2020-12-31 F1 · derivative.exercise_price: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award. F4 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F6 · derivative.exercise_price: The restricted stock unit vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award. F1 · derivative.exercise_date: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award. F4 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F6 · derivative.exercise_date: The restricted stock unit vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document
November 20, 2019 Filed Jan 4, 2020 01:37 UTC Amendment	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	12,373	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000035 · wf-form4a_157810184271109.xml · derivative · entry 1 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,373 Underlying: Common Stock, $0.10 par value · 12,373 shares Expires 2019-12-31 F1 · derivative.exercise_price: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award. F2 · derivative.exercise_price: Due to an administrative delay in calculations surrounding the total Merger Consideration (defined below) received by the Reporting Person, this Form 4 is being amended to report the correct number of securities beneficially owned by the Reporting Person as well as the correct expiration date for a few of the awards. F3 · derivative.exercise_price: Pursuant to the Merger, each outstanding share of Celgene common stock, par value $0.01 per share, was converted into the right to receive (x) $50 in cash, without interest, (y) one share of BMS common stock, par value $0.10 per share and (z) one tradeable contingent value right ( "CVR") per share or, with respect to equity awards (in some cases), per share underlying each such equity award ("Merger Consideration"). Each CVR will represent the right to receive $9.00 in cash upon Federal Drug Administration ("FDA") approval of a specified set of milestones, as set forth in the Contingent Value Rights Agreement, dated as of November 20, 2019, between BMS and Equiniti Trust Company, as trustee. F4 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F5 · derivative.exercise_price: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award. F1 · derivative.exercise_date: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award. F4 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F5 · derivative.exercise_date: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document
August 01, 2019 Filed Aug 5, 2019 16:00 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionRestricted Stock Unit · Derivative	24,947	$0.00	$0.00	Disclosure SEC source: 0001415889-19-000897 · form4-08052019_040802.xml · derivative · entry 4 Elkins David V · CIK 0001451604 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,895 Underlying: Common Stock · 24,947 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on August 1, 2018 have vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_price: The balance of the restricted stock units will vest as follows: 24,947 shares on August 1, 2020 and 24,948 shares on August 1, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date. F4 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on August 1, 2018 have vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on August 1, 2018 have vested and settled for shares of the Company's common stock. Read SEC document
August 01, 2019 Filed Aug 5, 2019 16:00 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Tax withholdingCommon Stock	11,039	$93.05	$1,027,178.95	Disclosure SEC source: 0001415889-19-000897 · form4-08052019_040802.xml · nonDerivative · entry 2 Elkins David V · CIK 0001451604 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,908 Read SEC document
August 01, 2019 Filed Aug 5, 2019 16:00 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionCommon Stock	24,947	$0.00	$0.00	Disclosure SEC source: 0001415889-19-000897 · form4-08052019_040802.xml · nonDerivative · entry 1 Elkins David V · CIK 0001451604 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: One-third of the restricted stock units granted to the reporting person on August 1, 2018 have vested and settled for shares of the Company's common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document
March 01, 2019 Filed Mar 5, 2019 16:05 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantRestricted Stock Unit · Derivative	39,642	$0.00	$0.00	Disclosure SEC source: 0001415889-19-000252 · form4-03052019_040324.xml · derivative · entry 1 Elkins David V · CIK 0001451604 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,642 Underlying: Common Stock · 39,642 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F2 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments, beginning on March 1, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. F2 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments, beginning on March 1, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.